Journal of Clinical Trials
Open Access
ISSN: 2167-0870
ISSN: 2167-0870
Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky, USA
Research Article
Ureaplasma, Azithromycin, and Varying Definitions of BPD (Bronchopulmonary Dysplasia) in Preterm Infants: Challenges for Clinical Care and Drug Development
Author(s): Maher Ajour, Yasir Alsiraj, Aric Schadler, Hong Huang, Brandon Schanbacher, Kori Williams, Hubert O. Ballard and John Anthony Bauer*
Rationale: Bronchopulmonary Dysplasia (BPD) is the major pulmonary morbidity in preterm infants, with the
defining criteria for this condition changing several times. Perinatal Ureaplasma infection has been implicated in
BPD risks and known to be prevalent in Neonatal Intensive Care Unit (NICU) patient populations. Some studies
have suggested the use of Azithromycin can reduce BPD risks in Ureaplasma positive cases.
Objectives: The goal of this study was to conduct a secondary data analysis using a completed clinical trial to
compare the incidence and severity of BPD in preterm infants using multiple BPD definitions.
Methods and results: Secondary data analysis including 220 preterm infants enrolled at birth and randomized
to receive Azithromycin or placebo daily up to 6 weeks was evaluated. Categorical .. View More»
DOI:
10.35248/2167-0870.23.13.536